See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
US Politics
Republican Party
Democratic Party
Tariffs
Donald Trump
Senate
US Economy
Tesla
Elon Musk
Stock Markets
White House
Social Media
Published • loading... • Updated

ITGA3 Promotes Pancreatic Cancer Progression through HIF1α- and C-Myc-Driven Glycolysis in a Collagen I-Dependent Autocrine Manner

Summary by Stemwell Science News
Investigators found that integrin subunit alpha 3 (ITGA3) expression was elevated in pancreatic cancer tissues and predicted poor prognosis for patients with pancreatic cancer. [Cancer Gene Therapy] Abstract
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
News.roNews.ro

Octav Ginghină, oncologist surgeon: The war with pancreatic cancer is a more difficult one. If in other pathologies, chemotherapy and immunotherapy have made great progress, in the pancreas, things are going quite slowly

Doctor Octav Ginghină, an oncologist surgeon, states that, unlike other pathologies in the oncological field, where great progress has been made, the statistics regarding pancreatic cancer are not as good. The doctor emphasizes, however, that there are patients with this disease who are "success stories."

Read Full Article
Stemwell Science NewsStemwell Science News

ITGA3 Promotes Pancreatic Cancer Progression through HIF1α- and C-Myc-Driven Glycolysis in a Collagen I-Dependent Autocrine Manner

Investigators found that integrin subunit alpha 3 (ITGA3) expression was elevated in pancreatic cancer tissues and predicted poor prognosis for patients with pancreatic cancer. [Cancer Gene Therapy] Abstract

Read Full Article
Pancreatic Cancer Action NetworkPancreatic Cancer Action Network

Research Spotlight - Pancreatic Cancer: A Look Back at 2024

Dec 17, 2024 - By Anna Berkenblit, MD, MMScWhile pancreatic cancer remains one of the toughest cancers to treat and is predicted to become the second-leading cause of cancer-related death in the U.S. before 2030, research and treatment advances in 2024 give us hope. This past year we have four new drug approvals for pancreatic cancer (one in the first-line setting and three targeted agents for previously treated cancer), a randomized phase 3 cli…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pancreatic Cancer Action Network broke the news in on Tuesday, December 17, 2024.
Sources are mostly out of (0)

Similar News Topics

Cancer

Cancer

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal